True North Expands Leadership Team to Advance Pipeline of Novel Rare Disease Treatments Targeting the Complement System
Adds Experienced Biotechnology Executives with Regulatory, Commercial and Clinical Expertise
South San Francisco, CA, April 5, 2017 — True North Therapeutics, a clinical stage biotechnology company developing novel product candidates that selectively inhibit the Complement system, today announced the expansion of its leadership team with the appointment of Michelle Carpenter, Vice President of Regulatory Affairs and Project Management, Kathy Dong, Vice President of Commercial Development and Shaily Garg, Vice President of Clinical Development.
“We are delighted to welcome Michelle, Kathy and Shaily to the True North team during this important time for the company,” said Nancy Stagliano, PhD, Chief Executive Officer of True North Therapeutics. “Their collective experience across regulatory, commercial and clinical functions will be instrumental as we advance our lead program, TNT009, for the treatment of patients with Cold Agglutinin Disease and evaluate its potential in additional Complement-mediated rare diseases.”
Michelle Carpenter is a regulatory affairs professional with over 25 years of biopharmaceutical experience, most recently as Vice President of Regulatory Affairs at Afferent Pharmaceuticals where she was responsible for setting and implementing global regulatory strategy. Prior positions include President, RPSpharma, a regulatory consulting firm, SVP of Regulatory Affairs and Clinical Development for Acucela, and a number of additional management positions in innovative Bay Area biotech companies. Michelle holds a JD from Golden Gate University School of Law, with an emphasis in Health Law.
Kathy Dong has more than 10 years of commercial experience within the biopharmaceutical industry, most recently as Director of HCV Marketing at Gilead Sciences where she was instrumental in developing and executing promotional strategies and tactical plans for Gilead’s HCV franchise, including the SOVALDI, HARVONI and EPCLUSA launches. She has experience commercializing products across a wide range of therapeutic areas and product lifecycle stages. Kathy holds a Doctor of Pharmacy and Masters in Business Administration from the University of New Mexico, and completed a post-doctoral fellowship at Novartis Pharmaceuticals and Rutgers University.
Shaily Garg has over 20 years of experience managing biopharmaceutical clinical development programs, most recently as Vice President of Clinical Development and Regulatory Affairs at Vaxart Inc. At Vaxart, she played a leadership role in managing the clinical strategy and operations of the company’s oral vaccine platform. Prior to joining Vaxart, Shaily held senior management positions within clinical and regulatory at Pacira Pharmaceuticals and Cerimon Pharmaceuticals. Shaily holds a BS in Biochemistry from the University of California, Davis.
About True North Therapeutics
True North Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class product candidates for Complement-mediated diseases. The company’s lead product candidate, TNT009, is designed to selectively inhibit a target in the Classical Complement pathway. True North’s antibody drug development is focused on the treatment of certain rare diseases mediated by the Complement system. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.
SOLVADI, HARVONI and EPCLUSA are registered trademarks of Gilead Sciences.
The Yates Network